- Report
- May 2024
- 213 Pages
Global
From €4467EUR$4,995USD£3,819GBP
- Report
- June 2025
- 89 Pages
North America
From €3085EUR$3,450USD£2,638GBP
- Report
- May 2025
- 132 Pages
Global
From €4337EUR$4,850USD£3,708GBP
- Report
- January 2024
- 120 Pages
United States
€3130EUR$3,500USD£2,676GBP
- Drug Pipelines
- February 2019
- 43 Pages
Global
From €8943EUR$10,000USD£7,646GBP
Jardiance is a medication used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, which work by blocking the reabsorption of glucose in the kidneys, allowing it to be excreted in the urine. This helps to lower blood sugar levels. Jardiance is typically used in combination with other diabetes medications, such as metformin, to help control blood sugar levels.
Jardiance is part of a larger market of endocrine and metabolic disorder drugs, which includes medications used to treat conditions such as obesity, thyroid disorders, and polycystic ovary syndrome. These drugs are used to help regulate hormones and metabolism, and can help to improve overall health and quality of life.
Companies in the Jardiance market include Boehringer Ingelheim, Merck, and Eli Lilly. Show Less Read more